Introduction: Calcium supplementation is one of the most important factors in maintaining the safety and efficacy of regional citrate anticoagulation (RCA) during continuous renal replacement therapy (CRRT). The aims of this study were to assess the determinants of calcium requirements in RCA-CVVH and to simplify the calcium supplementation approach. Methods: Our study consisted of two parts. The first part was a discovery phase to determine the key factors of calcium supplementation. Twenty critically ill patients who required RCA-CVVH were enrolled in this part. Systemic citrate, total calcium, protein-bound calcium, and ionized calcium concentrations were serially measured using the traditional RCA protocol. A two-phase calcium supplementation protocol was then proposed, and algorithms were developed for calcium supplementation. The second part of the study was the validation phase. Another 97 critically ill patients were enrolled and were treated with RCA-CVVH using the new version of the calcium supplementation protocol. Findings:The loss of calcium flux in the extracorporeal circuit and the increase in citrate-calcium complexes in vivo were the main determinants of the required calcium supplementation. In the CVVH mode, the rate of calcium infusion had to be reduced after systemic citrate level reached a steady state. With the aid of mathematical models, systemic calcium levels could be stably maintained in the normal range, and the frequencies of calcium monitoring were reduced. Discussion:Calcium supplementation during RCA-CVVH undergoes two phases. We propose mathematical models to quantify the need for calcium supplementation, which enable individualization of the RCA prescription and simplify the management of RCA in the CVVH mode.
INTRODUCTION
Continuous renal replacement therapy (CRRT) has been widely applied for the management of severe acute kidney injury (AKI) in critically ill patients with hemodynamic instability and multiple organ dysfunction syndrome (MODS). [1] [2] [3] A potential disadvantage of CRRT, however, is the need for prolonged anticoagulation to prevent extracorporeal circuit clotting. Heparin is the most commonly used anticoagulant in CRRT, but bleeding is reported to occur in up to 30% of treatments. [4] [5] [6] [7] Regional citrate anticoagulation (RCA), which restricts its powerful antithrombotic effect to the extracorporeal circuit, provides an excellent approach to avoid exposure to heparin during CRRT. However, the use of RCA in CRRT is not widely clinically applied due to metabolic complications and the complexity of existing protocols. A number of reported RCA protocols lack standardization and can hardly be performed in other dialysis centers because they largely depend on local habits and conditions. 8 Many centers have reported that the calcium infusion rate needs to be adjusted based on repeated measurements of ionized calcium concentrations both in vivo and in an extracorporeal circuit, which increases the complexity and workload of the practice of RCA.
The aims of this study were to assess the determinants of calcium supplementation in continuous veno-venous hemofiltration using RCA and to improve the protocol of calcium delivery.
MATERIALS AND METHODS

Patients
Adult critically ill patients who required CRRT were enrolled in the study. Written informed consent was obtained from either a close relative or a legal representative of each patient. Exclusion criteria included liver failure, severe alkalosis (pH > 7.55) or acidosis (pH <7.1), and death within 48 h. In the discovery phase, 20 patients were treated with a traditional RCA protocol. The median age was 63 AE 13 years old. Fifteen patients were AKI, and five were chronic kidney failure. Seven patients were mechanically ventilated. Eight patients were using vasopressors. In the validation phase, another 97 critically ill patients were enrolled and were treated with a novel calcium supplementation protocol. The patients' baseline characteristics are summarized in 
CVVH protocol
CVVH was performed using a Diapact CRRT machine (B. Braun, Germany) equipped with a HIPS 15 dialyzer (Diacap Polysulfone, B. Braun, Melsungen, Germany). The blood flow rate was set at 150-200 ml/min. The calcium-free substitution fluid was delivered into the extracorporeal circuit proximal to the filter with the fluid rate fluid of 4 L/h. The substitution fluid was calcium free and contained 121 mmol/L sodium, 3.0 mmol/L potassium, 0.75 mmol/L magnesium, 109 mmol/L chloride, 18 mmol/L bicarbonate, and 250 mg/dl of dextrose. The blood flow, ultrafiltration, and fluid replacement rates were recorded hourly.
The traditional citrate anticoagulation protocol
Trisodium citrate solution (4%, 136 mmol/L) was infused into the arterial line prior to the blood pump at a dose of 4 mmol/L of plasma flow. Calcium chloride solution (5% 340 mmol/L elemental calcium) was infused into the venous return to maintain systemic ionized calcium in the normal range (1.0-1.2 mmol/L). The rate of calcium infusion was adjusted in a timely manner based on repeated measurements of calcium concentration. The traditional calcium supplementation protocol was performed as described in Table 2 .
The two-phase calcium supplementation protocol and model development for RCA-CVVH
In most sessions of RCA-CVVH, we found that the calcium infusion rate had to be decreased at the third hour of treatment. Therefore, a two-phase calcium supplementation protocol for RCA-CVVH was proposed. Vasopressor using(n) 8 16 Furthermore, we developed mathematical models to quantify the calcium dosing corresponding to these two phases during RCA-CVVH (see the Appendix for details). An overview of the development of the RCA model is illustrated in Figure 1 . Given the patients' available clinical characteristics (i.e., hematocrit, plasma total protein concentration, and total calcium concentration) and the treatment parameters of CVVH, the clinicians were able to predict the appropriate calcium infusion rates during RCA-CVVH.
Laboratory tests
Hematocrit and serum protein concentration were determined using standard laboratory techniques for all patients at baseline before treatment.
In the first phase of the study, blood samples were drawn from the following sites of the extracorporeal circuit at 0 h, 1 h, 2 h, 3 h, 6 h, 8 h, 12 h, and 24 h:
1. Arterial line prior to citrate infusion. 2. After citrate infusion and prior to the replacement fluid. Concentrations of citrate, electrolytes (total calcium, ionized calcium, sodium, and chloride ions), nonprotein-bound calcium and acid-base status were analyzed for each sample. 3. Samples draw from ultrafiltrate for the measurement of total calcium concentration.
In the second phase of the study, the first 20 consecutive patients enrolled were tested for systemic citrate, total calcium, and ionized calcium concentrations at 0 h, 1 h, 2 h, 3 h, 6 h, 8 h, 12 h, and 24 h. The acid-base status and electrolytes of the next 77 patients were monitored at intervals of 2-6 h.
Systemic and extracorporeal circuit ionized calcium, sodium, and chloride levels and acid-base status were measured immediately at the patient's bedside using an i-STAT 300 analyzer (Abbott Laboratories, Illinois). Plasma citrate concentrations were determined using an Agilent 2+ is less than 0.8 mmol/L, bolus CaCl 2 10 ml, and then increase CaCl 2 rate by 5 ml/h. Figure 1 The overview of the development of mathematical model for calcium supplementation in RCA-CVVH. Qpw (L/h) = plasma flow rate; Qb (L/h) = blood flow rate; Hct = hematocrit; CcaT_in (mmol/L) = the total calcium concentration at the inlet of hemofilter; CcaT_art (mmol/ L) = the total calcium concentration of the arterial line prior to the citrate infusion port; Qcit (L/h) = the trisodium citrate solution infusion rate; Qsub (L/h) = the substitution fluid flow rate; fa = the proportion of filterable calcium to total calcium in the hemofilter; Caflux (mmol/h) = the amount of calcium lost into ultrafiltrate; S = the sieving coefficient, S = (1 -protein-bound fraction) ≈ 1; Quf (L/h) = the ultrafiltration flow rate; Csys(t) (mmol/ L) = systemic plasma citrate concentration; Kf (L/h) = the plasma clearance of citrate on the filter; Kb (L/h) = the plasma clearance of citrate in the body; V (L) = the apparent volume distribution of citrate; G (mmol/h) = the citrate load that the amount of citrate enters the patients' body per hour; t (h) = the time of citrate infusion; BW(kg) = body weight; fb = the relationship between the increase of bound calcium concentration and the citrate plasma level over time; Css (cit) (mmol/L) = a steady-state concentration of citrate, which can be predicted by the citrate kinetic model; t(ss) (h) = the time for citrate to a steady state; Qca1 (mmol/ h) = the calcium supplementation rate in the first phase; Qca2(mmol/h) = the calcium supplementation rate in the second phase. The specimens were analyzed at a wavelength of 210 nm. The inter-assay and intra-assay coefficients of variation were less than 6% and 11%, respectively. Total calcium and nonprotein-bound calcium concentrations were measured using the O-Cresolphthalein Complexone (OCPC) method as recommended by the World Health Organization. Protein-bound calcium levels were calculated by subtracting ionized calcium and nonproteinbound calcium levels from total calcium levels. As a slight modification, 800 μL of OCPC (30 mg/L) containing 8-hydroxyquinoline (0.25 g/L, final concentration) was added to the 10-μL plasma samples. The concentration of total calcium was determined based on the absorbance at 570 nm. After deproteinization by ultrafiltration using a Vivaspin membrane with a cut-off value of 3000 Dalton, nonprotein-bound calcium concentrations were measured. The intra-and inter-assay coefficients of variation (CV%) were less than 7.6% and 12.3%, respectively.
Statistical analysis
Data are expressed as the means AE standard deviations. Correlations were measured using Pearson's or Spearman's correlation coefficient. Values of P < 0.05 were considered significant.
RESULTS
Systemic citrate concentration
The mean citrate concentrations at different time points during the first 24 h of RCA-CVVH are shown in Figure 2 . In the first hour of RCA-CVVH, the systemic citrate concentration increased rapidly from the basal level (0.12 AE 0.17 mmol/L) to 0.47 AE 0.29 mmol/L. At the third hour of the treatment, the systemic citrate concentration was 0.77 AE 0.58 mmol/L. The mean systemic citrate concentration was 0.80 AE 0.35 mmol/L at the end of the RCA-CVVH treatment.
Calcium concentration and calcium infusion rate
Systemic citrate, total calcium, ionized calcium concentration, and calcium infusion rate during the first 24 h of RCA-CVVH are shown in Figure 3 . The mean initial calcium infusion rate was set at 8.21 AE 1.01 mmol/h. After 3 h of treatment, the mean calcium supplementation rate decreased to 6.8 AE 0.76 mmol/h. The average extracorporeal loss of calcium was 6.1 AE 0.9 mmol/h. The calcium supplementation presented a two-phase pattern:
1. At the beginning of the treatment, the calcium supplementation dose was higher than the extracorporeal loss. 2. As the citrate concentration reached a steady state after 3 h of treatment, the calcium supplementation dose was lower and was equal to the loss to ultrafiltration.
Filterable calcium and the increase of bound calcium during RCA-CVVH
At baseline, 37% AE 2% of calcium in the systemic blood was bound to proteins and could not cross the filter. After the citrate infusion site in the arterial line, the level of ionized calcium fell to 0.2-0.4 mmol/L as the level of citrate-calcium bound complexes increased. As the levels of the other small anions (e.g., phosphate, lactate, and sulfate) were relatively low, the mobile calcium that can cross the filter membrane freely consists of nonproteinbound calcium (mainly in the form of citrate-calcium complexes) and ionized calcium. The proportion of mobile calcium increased to 87% AE 1% of total calcium (Figure 4) . No statistical correlation was found between systemic plasma citrate and total calcium levels (P = 0.091), and between systemic plasma citrate and ionized calcium levels (P = 0.863). However, the increase in the concentration of bound calcium was correlated with the systemic citrate concentration (r = 0.7, P < 0.001). A linear regression equation was determined as follows: ΔCca-(bound) (t) = 0.062 + 0.778 × Ccit(t).
Validation of the two-phase calcium supplementation protocol and the mathematical model
The two-phase calcium supplementation protocol was validated in another 97 critically ill patients who were treated with RCA-CVVH. The rate of calcium supplementation was set based on the mathematical models. Figure 5 shows that the systemic total calcium and ionized calcium concentrations were stably maintained in a safe range. None of the hemofilters failed due to clotting during the treatment. We did not observe any episode of severe calcium disorder ( Figure 6 ). The calcium infusion rate only needed to be adjusted once or twice. Moreover, because the calcium concentration was stable, the frequency of calcium monitoring was lower than that required when using the traditional method. The frequency of calcium monitoring could be extended from once every 2 h to once every 6 h.
DISCUSSION
It has been shown that RCA has some advantages compared to heparin, such as the prolongation of circuit life, reduced bleeding complications, 10, 11 and improved hospital survival. 12 The 2012 Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines for AKI suggest RCA as the preferred anticoagulation approach for CRRT in patients without contraindications for citrate. 13 In most cases, citrate and calcium are infused separately; citrate is infused prefilter, and calcium is infused postfilter. Some protocols suggest a fixed citrate-to-blood flow ratio, which to some extent simplifies RCA management.
14 Calcium supplementation is usually applied empirically therefore, the calcium infusion rate needs to be adjusted based on the repeated calcium level monitoring. Indeed, the traditional calcium substitution protocols Figure 4 The proportion of ionized calcium, protein bound calcium, and nonprotein bound calcium in total calcium during RCA-CVVH. Ionized calcium and nonprotein bound calcium can freely cross the membrane. P1 = sampling port 1, the arterial line prior to the citrate infusion site = P2: sampling port 2, the site after the citrate infusion. Data are means AE SD. (n for each sampling point = 20). Figure 5 The systemic total calcium, ionized calcium level, and citrate infusion rate during RCA-CVVH using the two phase calcium supplementation protocol (Npatients = 20, 20 consecutive enrolled critically ill patients in the second part of study). Data are means AE SD. The rate of blood flow and the substitution fluid were set at 150-200 ml/min andhave two main disadvantages. First, the initial calcium replacement rate is usually set at the same rate and then adjusted according to the measured ionized calcium concentration. Second, the appropriate dose of calcium substitution and the time of adjusting the calcium infusion rate are empirically defined. In this study, we observed that the calcium supplementation during RCA-CRRT presented a two-phase pattern. The calcium infusion rate was initially higher than the extracorporeal loss but had to be decreased after 3 h of treatment as systemic citrate levels reached a steady state.
This phenomenon is consistent with citrate pharmacokinetics. At the start of RCA, hypocalcaemia tends to occur due to the formation of citrate-calcium complexes and the clearance of calcium by the hemofilters. 15 As the citrate concentration increases, a fraction of the calcium accumulates in the form of citrate-calcium complexes. During the course of citrate metabolism, this calcium fraction is gradually released and returns to the body pool. 16 The two-phase calcium supplementation pattern during RCA-CVVH are cause by the metabolism of citrate and the release of calcium from calcium-citrate complexes. Based on the half-life of citrate in critically ill patients without severe liver dysfunction, achieving a citrate steady state requires approximately 3 h. 17 As described by Justyna Kozik-Jaromin 15 , systemic citrate concentrations are rather low during 4 h of high-flux dialysis. In addition, these authors proposed that calcium loss through dialysis should be considered when estimating the initial calcium supplementation rate. In our study, we observed that the mean peak concentration of systemic citrate during CVVH was more than doubled. This might be due to the low efficiency of citrate clearance, the prolonged treatment process, and the potential for impaired citrate metabolism in critically ill patients. Therefore, in CVVH, to prevent hypocalcaemia due to a negative calcium balance, the extent of the increase in bound calcium (mainly in the form of citratecalcium complexes) and the amount of extracorporeal calcium loss should be considered when calculating the starting calcium supplementation dose. Due to citrate metabolism, the calcium infusion, the calcium liberated from citrate, and the extracorporeal calcium removal, a balance is achieved. Thus, to avoid a calcium overdose, the calcium infusion rate should be reduced such that it only replaces the extracorporeal calcium loss when a steady state of citrate metabolism is reached.
Thus, we proposed a two-phase calcium supplementation protocol based on the citrate metabolism and kinetics. Furthermore, to improve the accuracy of calcium delivery during RCA-CVVH, we integrated the two main determinants of calcium need into a mathematical model to quantify the calcium delivery. Given the patients' available clinical characteristics (i.e., hematocrit, plasma total protein concentration, total calcium concentration, citrate pharmacokinetics in the critically ill, and CVVH treatment parameters), the mathematical model can provide an individual prescription regarding the RCA protocol.
This study had the following unavoidable limitations. First, the calcium buffer capacity of bone was not considered in the proposed mathematical model. A study by van der Voort et al 18 showed a persistently high PTH during 48 h CRRT with RCA, which was a reaction to negative calcium balance. Wang 19 observed that a critically ill patient undergoing prolonged CRRT with citrate anticoagulation was able to achieve normalized systemic calcium levels without calcium replacement 8 weeks after the initiation of CRRT, suggesting that high bone turnover rates played an important role. Thus, bone metabolism should be considered if CRRT is prolonged for more than 24 h. In the current study, the proposed two-phase models are only valid for the first 24 h of CVVH, and the models should be modified due to the participation of bone metabolism. Second, the application of the mathematical model for estimating the starting dose of calcium supplementation depends on citrate pharmacokinetics. To date, Kramer et al. 17 and our research group 9 have reported citrate pharmacokinetics in critically ill patients with cirrhosis and acute kidney injury. Theoretically, critically ill patients with microcirculation failure, hypoxemia, and septic shock may have impaired citrate metabolism. Systemic studies of citrate kinetics in these populations are required. Third, since the filter was changed every 24 h and no treatment session was discontinued for unexpected reasons, the sieving coefficient of citrate-calcium complexes was assumed to be constant unit. As reported by Macedo E, et al. 20 , even when adequate anticoagulation with citrate was used during CRRT, a progressive loss of filter efficacy occurred, and the sieving coefficient for small solutes declined over time. Therefore, we suggest changing the filter at least every 24 h.
In conclusion, this study demonstrates that the calcium delivery during RCA-CVVH undergoes two phases, which are correlated with citrate kinetics. The two-phase calcium supplementation protocol was rational and labor-saving. The mathematical model improved the accuracy and safety of the calcium supplementation. We believe that this model will be a useful tool in the clinical application of RCA-CVVH. where. fa: the proportion of filterable calcium to total calcium in the hemofilter.
fb: the relationship between the increase in the amount of bound calcium concentration and the citrate plasma level over time.
Qca 1 (mmol/h): the calcium supplementation rate during the first phase.
t (ss) (h): the time for citrate to reach a steady state. According to the half-life of citrate in critically ill patients without severe liver dysfunction, it requires about 3 h to reach a citrate steady state. 17 CcaT_art (mmol/L): the total calcium concentration in the arterial line prior to the citrate infusion port.
As the steady-state of citrate is reached, the rate of calcium infusion should be reduced to the amount of calcium loss into the ultrafiltrate, which can be estimated using Equation 5 as follows: 
